Redefining Diabetic Treatment, Revolutionizing Healthcare, and Upholding Ethical Innovation: Söylemez Investment

Söylemez Investment, founded by Dr. Mehmet Ali Soylemez, stands at the forefront of technological innovation with a mission to accelerate progress across various industries. Recognized for its groundbreaking contributions, particularly in advancing diabetic treatments, the firm has earned accolades such as the Innovation Excellence Awards. Driven by a commitment to constant improvement, Söylemez Investment is dedicated to pushing the boundaries of what's possible, fostering collaboration, leaving a lasting impact on the realms of healthcare and beyond.

Dr. Mehmet Ali Soylemez, Managing Director of Söylemez Investment, spoke exclusively to CIO Bulletin about how he and his company are revolutionizing healthcare practices and improving the lives of countless individuals.

Revolutionizing Healthcare and Technology: The Visionary Journey of Dr. Mehmet Ali Söylemez

Embarking on a visionary journey, Dr. Mehmet Söylemez founded Söylemez Investment with a resolute mission—to propel the advancement of pivotal technologies across diverse industries. Fueled by a passion for collaboration and an unwavering commitment to enhancing diabetic treatments, Söylemez Investment garnered well-deserved recognition in the esteemed Innovation Excellence Awards for its instrumental role in driving progress throughout the broader industry.

Beyond his entrepreneurial pursuits, Dr. Söylemez stands as a distinguished Medical Doctor and Scientist, boasting an illustrious portfolio of achievements that have significantly shaped the landscape of healthcare. With expertise spanning Clinical Genetics, General Surgery, and Medical Physiology, he has become a trailblazer in the realm of medical science.

Dr. Söylemez's groundbreaking research and innovative discoveries stand as testament to his unwavering dedication. His profound impact on the diagnosis and management of Diabetes Mellitus and Diabetic Foot Syndrome underscores his commitment to revolutionizing healthcare practices and improving the lives of countless individuals. Join us as we delve into the remarkable journey of a visionary leader shaping the future of both technology and healthcare.

Revolutionizing Diabetic Treatment: The Pioneering Impact of Procalcitonin

From the outset, Dr. Mehmet Söylemez credits his most significant achievement as his pioneering work in identifying the utility of the biomarker procalcitonin in diabetes mellitus and diabetic foot syndrome. By all regards, this marks a considerable turning point in this sector, pushing forward our understanding of both complex medical conditions toward future development and more effective treatment. However, this is far from the only achievement of Mehmet and Söylemez Investment in this space.

“Indeed, the firm has made a swift impression with a host of similar developments, marking Söylemez Investment as a key player on the greater board. Today, the company boasts approximately 40 peer-reviewed publications on procalcitonin as a biomarker tool. What we’ve found, repeatedly, is this invention (procalcitonin) is more useful than HgbA1c. HgbA1c shows a potential diabetic complication over a period of three months, while this invention reveals a much smaller timeline – in the region of 24 hours – of potential damage from complications. So, diabetes mellitus and diabetic complications can be treated faster and much more successfully,” says Dr. Söylemez.

If examined the value proposition of this novel biomarker, its significance lies in its capacity to identify patients at risk of complications at an early stage, necessitating specific and tailored interventions. Current diagnostics may not detect these individuals, but our novel biomarker offers a holistic view, encompassing both the early and late phases of Diabetes Mellitus.

This development comes after two decades of work, despite considerable challenges and obstacles in bringing the efficacy of such a biomarker to the awareness of the greater market. Yet, this has almost become archetypal of Mehmet and Söylemez Investment’s portfolio – bringing greater awareness to key developments through diligent research and ‘signal boosting’ applicable technologies.

Moreover, Dr. Söylemez is the rightful owner of the patent for this groundbreaking invention, titled “Diagnosis of Pancreatic Diabetes in Patients with Normal Blood Leukocyte Counts Using Procalcitonin.” This patented invention is registered with the European Patent Office (EPO) under registration number EP2626704 B1, further highlighting the significance and uniqueness of his work. This patent is also protected within three national registries, including the United Kingdom, Sweden, and Turkey.

Ethical Innovation: The Foundation of Söylemez Investment's Commitment

Switching focus to Söylemez Investment and its overarching goals, Dr. Mehmet explains that it is, at its core, a family company operating in a wide range of industries, from real estate to IP investment. The latter is his main focus within the ‘family’, and he is open to collaboration with biotech and diagnostic firms worldwide seeking investment to accelerate their entry into the market. Complementing this goal is an ethos defined by ethical management and development, as Mehmet continues. “Our main values are respect for humans and respect for clients. Our scientific goal is to design an individual diagnostic treatment plan to help each and every one of our diabetic patients achieve the best outcome possible. That’s where our future lies,” explains Dr. Mehmet Söylemez.

With a foundation and mission directed towards advancing treatments for diabetes mellitus and diabetic foot syndrome – among many others in the same vein – Dr. Mehmet Söylemez is utilizing his knowledge and expertise to make real change in an industry that sorely needs every advantage it can gain.

Patenting Progress: Söylemez Investment's Breakthroughs in Diagnostic Biomarkers

The tireless dedication and pioneering research of Dr. Söylemez have led to the widespread use of the Biomarker Procalcitonin for diagnosing Diabetes Mellitus and Diabetic Foot Syndrome globally. His impactful work significantly contributes to the field of health sciences, enhancing the diagnosis and management of these conditions.

Söylemez Investment has submitted two patent applications to the UNITED STATES PATENT and TRADEMARK OFFICE (USPTO):

1. Titled, “Procalcitonin Gene Expression As a Precise Biomarker Of Aging Process,” with patent No: US 20130252254 A1  USPTO (United States Patent And Trademark OFFICE).
   
   
2. Titled “Diagnosis And Complication Risk Assessment Of Pancreatic Diabetes Using Procalcitonin” with patent No: US 20110263438 A1

The long-term strategic vision for Söylemez Investment is to secure these patents from the USPTO and gain access to the United States market.

“I envision that the future of diagnostic and preventive healthcare advancements will rely on diagnostic biomarkers and molecular genetics. Söylemez Investment must be prepared to evolve and adapt to these market changes in the next 5-10 years,” concludes Dr. Mehmet Ali Soylemez.

“Our main values are respect for humans and respect for clients. Our scientific goal is to design an individual diagnostic treatment plan to help each and every one of our diabetic patients achieve the best outcome possible. That’s where our future lies.”